# Public tenders Canonical results: https://zephior.com/tenders?categories=infectious-disease-research 1 matching notices. Page 1. Filter semantics: OR within a filter, AND across filters and text search. Omitted statuses use active defaults; [] includes all statuses. --- title: "NIAID broad agency announcement for infectious disease interventions" canonical: "https://zephior.com/tenders/a6fd8f90-0c96-40f9-a4d9-f79f192e23e3/niaid-medical-interventions-infectious-diseases-baa" last-updated: 2026-10-12T12:09:56.912760+00:00 --- # NIAID broad agency announcement for infectious disease interventions NIAID/DMID seeks proposals in three areas: needle-free vaccine candidates that include an early clinical trial; therapeutics for serious infectious diseases, including drug-resistant pathogens; and rapid, broadly applicable in-vitro diagnostics for viral pathogens. The notice gives detailed public objectives, scope and submission requirements, with proposals due 8 December 2026 at 3:00 PM Eastern Time via NIH’s eCPS system only. Comprehensive technical and evaluation requirements are in the referenced BAA solicitation, which was not opened. - Status: open - Country: US - Buyer: National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases - Submission deadline: 2026-12-08T15:00:00-05:00 (instant) - Original notice: https://sam.gov/opp/5f75330f42ee4145990fe6a51a3dc84e/view - Source checked: 2026-10-12T12:02:50.597817Z ## Source-backed public facts ```json { "id": "a6fd8f90-0c96-40f9-a4d9-f79f192e23e3", "revision": 1, "modifiedAt": "2026-10-12T12:09:56.912760+00:00", "sourceCheckedAt": "2026-10-12T12:02:50.597817Z", "stale": false, "url": "https://zephior.com/tenders/a6fd8f90-0c96-40f9-a4d9-f79f192e23e3/niaid-medical-interventions-infectious-diseases-baa", "locale": "en", "title": "NIAID broad agency announcement for infectious disease interventions", "summary": "NIAID/DMID seeks proposals in three areas: needle-free vaccine candidates that include an early clinical trial; therapeutics for serious infectious diseases, including drug-resistant pathogens; and rapid, broadly applicable in-vitro diagnostics for viral pathogens. The notice gives detailed public objectives, scope and submission requirements, with proposals due 8 December 2026 at 3:00 PM Eastern Time via NIH’s eCPS system only. Comprehensive technical and evaluation requirements are in the referenced BAA solicitation, which was not opened.", "status": "open", "recordedStatus": "open", "sourceStatus": "open", "country": "US", "buyer": { "id": "nih-niaid-dmid", "name": "National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases" }, "category": { "de": "Forschung zu Infektionskrankheiten", "en": "Infectious disease research", "fr": "Recherche sur les maladies infectieuses", "id": "infectious-disease-research" }, "deadline": { "at": "2026-12-08T15:00:00-05:00", "date": null, "source_ref": "official_notice_detail", "sourceRef": "official_notice_detail", "collectorValue": "2026-12-08T20:00:00+00:00", "precision": "instant", "displayTimeZone": "visitor browser time zone for exact timestamps; date-only deadlines retain their calendar date", "semantics": "at or date is the reviewed deadline from the cited source. collectorValue is what the collector parsed; it can show a date-only deadline as local midnight, so prefer at or date when they differ." }, "originalSource": { "url": "https://sam.gov/opp/5f75330f42ee4145990fe6a51a3dc84e/view", "title": "2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases", "issuer": "HEALTH AND HUMAN SERVICES, DEPARTMENT OF.NATIONAL INSTITUTES OF HEALTH.NATIONAL INSTITUTES OF HEALTH NIAID", "status": "open", "language": "en", "location": null, "deadline_at": "2026-12-08T20:00:00+00:00", "description": null, "country_code": "US", "published_at": "2026-10-09T00:00:00+00:00", "contract_type": "service", "deadline_date": null, "procedure_type": "Solicitation", "reference_numbers": [ "5f75330f42ee4145990fe6a51a3dc84e", "HHS-NIH-NIAID-BAA2026-1" ], "classification_codes": [ { "code": "541715", "system": "NAICS", "provenance": "source_declared" }, { "code": "AN12", "system": "PSC", "provenance": "source_declared" } ] }, "sourceName": "SAM.gov", "sources": [ { "ref": "canonical_snapshot", "url": "https://sam.gov/opp/5f75330f42ee4145990fe6a51a3dc84e/view", "kind": "canonical_snapshot", "retrieved_at": "2026-10-12T12:01:26.733884Z" }, { "ref": "official_notice_detail", "url": "https://sam.gov/opp/5f75330f42ee4145990fe6a51a3dc84e/view", "kind": "official_notice_html", "retrieved_at": "2026-10-12T12:02:50.597817Z" } ], "content": { "title": "NIAID broad agency announcement for infectious disease interventions", "summary": "NIAID/DMID seeks proposals in three areas: needle-free vaccine candidates that include an early clinical trial; therapeutics for serious infectious diseases, including drug-resistant pathogens; and rapid, broadly applicable in-vitro diagnostics for viral pathogens. The notice gives detailed public objectives, scope and submission requirements, with proposals due 8 December 2026 at 3:00 PM Eastern Time via NIH’s eCPS system only. Comprehensive technical and evaluation requirements are in the referenced BAA solicitation, which was not opened.", "key_facts": [ { "label": "Proposal deadline", "value": "8 December 2026, 3:00 PM Eastern Time", "source_ref": "official_notice_detail" }, { "label": "Submission channel", "value": "NIH eCPS only", "source_ref": "official_notice_detail" }, { "label": "Research areas", "value": "Needle-free vaccines; therapeutics; in-vitro diagnostics", "source_ref": "official_notice_detail" }, { "label": "Clinical expectation", "value": "Vaccine proposals include a clinical trial; therapeutics support early clinical studies", "source_ref": "official_notice_detail" }, { "label": "Diagnostic targets", "value": "Broad viral families; rapid sample-to-answer platform", "source_ref": "official_notice_detail" } ], "notice_analysis": { "scope": "Broad agency announcement for medical interventions against infectious diseases across three research areas: needle-free vaccines; therapeutics for serious infections; and in-vitro diagnostics for viral pathogens.", "missing_information": [ "The full BAA solicitation contains comprehensive project requirements, technical objectives, proposal instructions and evaluation process and was not opened. No funding amount or award is stated in the public notice." ], "participation_requirements": [ "Proposals must be submitted online through NIH eCPS; other methods are not permitted. The notice describes research-area objectives and clinical/technical expectations; the referenced full BAA solicitation contains comprehensive requirements, submission instructions and evaluation details and was not opened." ] } }, "facts": { "lots": [], "schedule": [ { "event": "Proposal deadline", "value": "Dec 8, 2026 3:00 PM Eastern Time", "source_ref": "official_notice_detail" } ], "requirements": [ { "text": "Proposals must be submitted online through NIH eCPS; other methods are not permitted. The notice describes research-area objectives and clinical/technical expectations; the referenced full BAA solicitation contains comprehensive requirements, submission instructions and evaluation details and was not opened.", "source_ref": "official_notice_detail" } ], "award_criteria": [], "estimated_value": null }, "award": null, "contractPeriod": null, "noticeText": { "text": "2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases\nACTIVE\nContract Opportunity\nNotice ID\nHHS-NIH-NIAID-BAA2026-1\nRelated Notice\nDepartment/Ind. Agency\nHEALTH AND HUMAN SERVICES, DEPARTMENT OF\nSub-tier\nNATIONAL INSTITUTES OF HEALTH\nOffice\nNATIONAL INSTITUTES OF HEALTH NIAID\nGeneral Information\nContract Opportunity Type: Solicitation (Original)\nOriginal Published Date: Oct 09, 2026 04:58 pm EDT\nOriginal Date Offers Due: Dec 08, 2026 03:00 pm EST\nInactive Policy: 15 days after date offers due\nOriginal Inactive Date: Dec 23, 2026\nInitiative:\nNone\nClassification\nOriginal Set Aside: No Set aside used\nProduct Service Code: AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH\nNAICS Code:\n541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)\nPlace of Performance:\nDescription\n\nINTRODUCTION:\n\nThe National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate.\n\nThis Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation.\n\nAn offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process.\n\nPlease note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach. Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation.\n\nResearch Area 001 - Vaccine Candidates:\n\nThe objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses.  \n\nThe scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial.  The scope of work must include a clinical trial. \n\nOfferors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses.\n\nA strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery.\n\nResearch Area 002 - Therapeutic Candidates:\n\nThe objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted:\n\nViral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html\nEncephalitic paramyxoviruses (e.g. hendra virus, nipah virus)\nPicornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus)\nAt least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales\n\nAdjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered.\n\nImportant notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome.\n\nPreventative treatments are not included in the scope of this Research Area.\n\nA therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of